Final report of the safety assessment of allantoin and its related complexes

International Journal of Toxicology

Volumn 29, Issue 3_suppl, 2010, Pages 84S-97S

  Becker, Lillian C ^a   Bergfeld, Wilma F ^a   Belsito, Donald V ^a   Klaassen, Curtis D ^a   Marks, James G ^a   Shank, Ronald C ^a   Slaga, Thomas J ^a   Snyder, Paul W ^a   Andersen, F Alan ^a  

^a Cosmetic Ingredient Review ^*  (United States)

Author keywords

allantoin; cosmetics; safety

Indexed keywords

ALLANTOIN; ASCORBIC ACID; BIOTIN; DEXPANTHENOL; GALACTURONIC ACID; GLYCYRRHETINIC ACID; POLYGALACTURONIC ACID; COSMETIC; DERMATOLOGICAL AGENT; DRUG DERIVATIVE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DANDRUFF; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; EXTRACTION; FEMALE; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; MELTING POINT; MOLECULAR WEIGHT; NONHUMAN; PH; PHOTOTOXICITY; PHYSICAL PHENOMENA; POTENTIOMETRIC TITRATION; POWDER; PSORIASIS; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RISK ASSESSMENT; SEBORRHEIC DERMATITIS; SOLUBILITY; THIN LAYER CHROMATOGRAPHY; VAPOR PRESSURE; ANIMAL; EXPERIMENTAL ANIMAL; HUMAN; REVIEW; SAFETY; TOXICITY TESTING;

ALLANTOIN; ANIMALS; ANIMALS, LABORATORY; CONSUMER PRODUCT SAFETY; COSMETICS; DERMATOLOGIC AGENTS; HUMANS; RISK ASSESSMENT; TOXICITY TESTS;

EID: 77955896977     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581810362805     Document Type: Article

References (99)

1. Andersen FA Final report on the safety assessment of l-asorbic acid, calcium ascorbate, magnesium ascorbate, magnesium ascorbyl phosphate, sodium ascorbate, and sodium ascorbyl phosphate as used in cosmetics. Int J Toxicol. 2005; 24: 51-111.
2. Andersen FA Final report on the safety assessment of biotin. Int J Toxicol. 2001; 20: 1-12.
3. Andersen FA Final report on the safety assessment of glycyrrhetinic acid, potassium glycyrrhetinate, disodium succinoyl glycyrrhetinate, glyceryl glycyrrhetinate, glycyrrhetinyl stearate, stearyl glycyrrhetinate, glycyrrhizic acid, ammonium glycyrrhizate, dipotassium glycyrrhizate, disodium glycyrrhizate, trisodium glycyrrhizate, methyl glycyrrhizate, and potassium glycyrrhizinate. Int J Toxicol. 2007; 26: 79-112.
4. Elder RL Final report on the safety assessment of panthenol and pantothetic acid. J Am Coll Toxicol. 1987; 6: 139-162.
5. Andersen FA Annual review of cosmetic ingredient safety assessments-2004/2005. Int J Toxicol. 2006; 25: 1-89.
6. Health and Human Services. Direct food substances affirmed as generally recognized as safe. Code Fed Regul. 2006; 184:(1588).
7. Gottschalck TE, Bailey JE International Cosmetic Ingredient Dictionary and Handbook. 12 th ed. Washington, DC: CTFA; 2008.
8. Sheker KM, Black HJ, Lach JL Silver allantoinate for the topical treatment of burns. Am J Hosp Pharm. 1972; 29: 852-855.
9. ChemicalLAND21. Allantoin. 2007. http://chemicalland21.com/lifescience/phar/ALLANTOIN.htm. Accessed January 1, 2007.
10. Fisher AA A non-sensitizing topical medicament therapeutic effects of the addition of 5 percent allantoin to Vaseline. Cutis. 1981; 27: 230-231, 234, 329.
11. Akema Fine Chemicals. Allantoin: a safe and effective skin protectant; 2006. Unpublished data.
12. Lesser MA Allantoin. Drug Cosmetic Ind. 1938; 42: 451-453, 456, 469.
13. Schali C., Roch-Ramel F. Renal handling of [14C] allantoin in the rabbit. J Pharmacol Exp Ther. 1980; 213: 168-172.
14. Buzard JA, Bishop C., Talbott JH The conversion of uric acid to allantoin in the normal and gouty human. J Biol Chem. 1954; 211: 559-611.
15. ChemIDplus Lite. Allantoin. 2007. http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFull.jsp?calledFrom=lite. Accessed January 1, 2007.
16. Mecca SB Allantoin in cosmetic formulations. Proceedings of the Scientific Section of the Toilet Goods Association. 1955; 23: 8-13.
17. Akema Fine Chemicals. Akema Fine Chemicals overview. 2007. http://www.akema.it/pdf/COMPANY-BROCHURE.pdf. Accessed December 1, 2007.
18. Mecca SB Allantoin and its derivatives. Cosmet Toilet. 1978; 93: 39-41.
19. Active Ingredients Ltd. Glyceratoin. 2004. http://www.activeingredient.plus.com/glyceratoin.pdf.
20. Givens MH Brief notes concerning allantoin. J Biol Chem. 1912; 18: 417-424.
21. Kaliszan R., Halkiewicz J. IR analysis of crystalline samples of some urea derivatives. Pol J Pharmacol Pharm. 1975; 27: 579-587.
22. Zaidi ZR, Sena FJ, Basilio CP Stability assay of allantoin in lotions and creams by high-pressure liquid chromatography. J Pharm Sci. 1982; 77: 997-999.
23. Sznitowska M., Janicki S. In vitro study of allantoin release from various ointment formulations. Pharmazie. 1987; 42: 62-63.
24. Lukasiak J., Jamrogiewicz Z., Sznitowska M. Some remarks on the UV spectrophotometric determination of allantoin. Pharmazie. 1987; 42: 200-201.
25. Livingston SK, Prince LH The treatment of chronic osteomylitis. JAMA. 1932; 98: 1143-1149.
26. Maksimovic Z., Malenovic A., Jancic B., Kovacevic N. Quantification of allantoin in various Zea mays L. hybrids by RP-HPLC with UV detection. Pharmazie. 2004; 59: 524-527.
27. Hartman WW, Moffett EW, Dickey JB Allantoin. Org Syntheses, Coll. 1943; 2: 21.
28. Akema Fine Chemicals. Allantoin CTFA; 2005. http://www.akema.it/allantoin.htm. Accessed January 1, 2007.
29. Weber DJ, Higgins JW Potentiometric titration of allantoin in cream formulation. J Pharm Sci. 1970; 59: 1819-1821.
30. Tiemeyer W., Giesecke D. Quantitative determination of allantoin in biological fluids by reversed-phase high-pressure liquid chromatography. Anal Biochem. 1982; 123: 11-13.
31. Grootveld M., Halliwell B. Measure of allantoin and uric acid in human body fluids. Biochem. 1987; 243: 803-808.
32. Kawase J., Ueno H., Tsuji K. Determination of allantoin and chlorohydroxy-aluminum allantoinate in cosmetic and pharmaceutical products by high-performance liquid chromotography. J Chromatog. 1982; 253: 237-242.
33. Lux O., Naidoo D., Salonikas C. Improved HPLC method for the simultaneous measurement of allantoin and uric acid in plasma. Ann Clin Biochem. 1992; 29: 674-675.
34. Chen XB, Matsuzewski W., Kowalczyk J. Determination of allantoin in biological, cosmetic, and pharmaceutical samples. J AOAC Int. 1996; 79: 628-635.
35. Berthemy A., Newton J., Wu D., Buhrman D. Quantitative determination of extremely polar compound allantoin in human urine by LC-MS/MS based on the separation on a polymeric amino column. J Pharm Biomed Anal. 1999; 19: 429-434.
36. Benzie IFF, Chung WY, Tomlinson B. Simultaneous measurement of allantoin and urate in plasma: analytical evaluation and potential clinical application in oxidant antioxidant balance studies. Clin Chem. 1999; 45: 901-904.
37. Marklund N., Östman B., Nalmo L., Persson L., Hillered L. Hypoxanthine, uric acid and allantoin as indicators of in vivo radical reactions: description of a HPLC method and human brain micro-dialysis data. Acta Neurochir. 2000; 142: 1142.
38. Pavitt DV, De Fonseka S., Al- Khalaf N., Cam JM, Reaveley DA Assay of serum allantoin in humans by gas chromatography- mass spectrometry. Clin Chim Acta. 2002; 318: 63-70.
39. Muratsubaki H., Satake K., Enomoto K. Enzymatic assay of allantoin in serum using allantoinase and allantoate amidohydrolase. Anal Biochem. 2006; 359: 161-166.
40. United States Pharmacopia. Allantoin. 2005: 1323-1324.
41. Kahn LP, Nolan JV Kinetics of allantoin metabolism in sheep. Br J Nutr. 2000; 84: 629-634.
42. Wang X. -C, Gui C. -Q, Zheng Q. -S. Combined therapy of allantoin metronidazole, dexamethasone on the prevention of intra-abdominal adhesion in dogs and in its quantitative analysis. World J Gastroenterol. 2003; 9: 568-565.
43. Ackroyd H. On the presence of allantoin in certain foods. Biochem J. 1911; 5: 400-406.
44. Zhang L., Liu Y., Chen G. Simultaneous determination of allantoin, choline, and l-arginine in Rhizoma Dioscoreae by capillary electrophoresis. J Chromatog A. 2004; 1043: 317-321.
45. Food and Drug Administration. Frequency of use of cosmetic ingredients. FDA Database. 2007.
46. Cosmetic, Toiletry and Fragrance Association. Concentration of use allantoin and related ingredients; 2007. Unpublished data.
47. Food and Drug Administration. Frequency of use of cosmetic ingredients. FDA Database. 2006.
48. Ministry of Health, Labor and Welfare. Unofficial Translation of MHLW Notification No 0524001 Regarding the Handling of Medicinal Ingredients That May Be Incorporated in Cosmetics. Tokyo, Japan: Pharmaceutical and Medical Safety Bureau, Inspection and Guidance Division; 2007.
49. Willeke K., Baron PA Industrial Hygiene: Aerosol Measurement: Principles Techniques and Applications. New York, NY: Wiley; 1993.
50. Lehman-McKeeman LD Absorption of Toxicants by the Lungs. In: Casarret and Doull's Toxicology: The Basic Science of Poisons. Klassen CD, ed. New York: McGraw-Hill; 2008: 140-142.
51. Bower D. Unpublished information on hair spray particle sizes provided at the September 9, 1999 CIR Expert Panel meeting; 1999.
52. Johnsen MA The influence of particle size. Spray Technology and Marketing. November 2004: 24-27.
53. Health and Human Services. Skin protectant active ingredients. Code Fed Regul. 2007; 347:(10).
54. Robinson W. Stimulation of healing in non-healing wounds. J Bone Joint Surg. 1935; 17: 267-262.
55. Morris GE Pedicuosis corporis and leg ulcers. N Engl J Med. 1945; 22: 180.
56. Margraf HW, Covey TH A trial of silver-zinc allantoinate in the treatment of leg ulcers. Arch Surg. 1977; 112: 699-704.
57. Koerber KA, Spangler HA, O'Donnell C., Moffses GH Sulfallantoin in industrial medicine. Industrial Med. 1942; 11: 475-476.
58. Health and Human Services. Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. Code Fed Regul. 2007; 310:(545).
59. Akema Fine Chemicals. Allantoin and derivatives. 2007. http://www.iper.net/akema/ALLANTOIN%20AND%20DERIVATIVES%20.htm. Accessed December 1, 2007.
60. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopuinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001; 97: 2998-3003.
61. Martens M. e, Storey BT, Lee CP Generation of allantoin from the oxidation of urate by cytochrome c and its possible role in Reye's syndrome. Arch Biochem Biophys. 1987; 252: 91-96.
62. Lagendijk J., Ubbink JB, Vermaak WJ The determination of allantoin, a possible indicator of oxidant status, in human plasma. J Chromatog Sci. 1995; 33: 186-193.
63. Hellsten Y., Tullston PIC, Richter EA, Bangsbo J. Oxidation of urate in human skeletal muscle during exercise. Free Rad Biol Med. 1997; 22: 169-174.
64. Kock R., Delvoux B., Sigmund M., Greiling H. A comparative study of the concentrations of hypoxanthine, zanthine, uric acid and allantoin in the peripheral blood of normals and patients with acute myocardial infarction and other ischaemic diseases. Eur J Clin Chem Clin Biochem. 1994; 32: 837-842.
65. Naidoo D., Lux O. The effect of vitamin C and E supplementation on lipid and urate oxidation products in plasma. Nutr Res. 1998; 18: 953-961.
66. Sznitowska M., Janicki S. The effect of vehicle on allantoin penetration into human skin from an ointment for improving scar elasticity. Pharmazie. 1988; 43: H3.
67. Young EG, Wentworth HP, Hawkins WW The absorption and excretion of allantoin in mammals. J Pharmacol Exp Ther. 1944; 81: 1-9.
68. Friedman M., Byers SO Clearance of allantoin in the rat and dog as a measure of glomerular filtration rates. Am J Physiol. 1947; 151: 192-197.
69. Wallenburg HCS, van Kreel BK Transfer and dynamics of uric acid in the pregnant rhesus monkey, I: transplacental and renal uric acid clearances. Eur J Obstet Gynecol Reprod Biol. 1978; 8: 211-217.
70. HF 0041-Evaluation de toxicite aigue chez le rat par voie orale. Study no. 1757 TAR. November 22, 1985. Allantoin compilation of toxicity studies. Clariant GmBH.
71. Allantoin (HF-0041)-Eye irritation study in the rabbit. Study no. 5420 TAR. September 28, 1989. Allantoin compilation of toxicity studies. Clariant GmbH.
72. Andrews AW, Lijinsky W., Snyder SW Mutagenicity of amine drugs and their products of nitrosation. Mutat Res. 1984; 135: 105-108.
73. Gus'kov EP, Kletskii ME, Korniendo IV, et al. Allantoin as a free-radical scavenger. Dokl Biochem. Biophys. 2002; 383: 105-107.
74. Shiseido Research Center. Safety data of allantoin; 2008. Unpublished data.
75. Gus'kov EP, Prokof'ev VN, Kletskii ME, et al. Allantoin as a vitamin. Dokl Biochem Biophys. 2004; 398: 320-324.
76. Lijinsky W. Induction of tumours in rats by feeding nitrosatable amines together with sodium nitrite. Food Chem Toxicol. 1984; 22: 715-720.
77. Friedman M., Byers SO, Abraham PM Allantoin clearance as a measure of glomerular filtration in man. Proc Soc Exp Biol Med. 1947; 66: 522-523.
78. Friedman M., Byers SO, Abraham PM Renal clearance of allantoin as a measure of glomerular filtration rate. Am J Physiol. 1948; 155: 278-281.
79. Mecca SB Allantoin and the newer aluminum allantoinates. Proc Sci Sec Toilet Goods Assoc. 1959;(31): 1-6.
80. Tronnier H. April 18, 1996. Epikutantest zur Prüfung der hautirritierenden Wirkung kosmetischer Produkte am Menschen-Allantoin. Institute für experimentelle Dermatologie, Uninversität Witten-Herdeck. Forschngsaufrag 57/4/96. Cited in Clariant GmbH. 2003 Allantoin compilation of toxicity studies. Unpublished data.
81. Consumer Product Testing Co. Exclusive repeated insult patch test. 2007. Unpublished data.
82. Personal Care Products Council. Summaries of products containing allantoin for the CIR review of allantoin and related ingredients. 2008. Unpublished data.
83. Mecca SB The function and applicability of the allantoins. Proc Sci Sec Toilet Goods Assoc. 1963; 39: 7-15.
84. Henning T. Evaluation of the efficacy of allantoin. Eur Cosmet. 2001; 2: 20-22.
85. Vinson J., Proch J. Inhibition of moisture penetration to the skin by a novel incontinence barrier product. J Wound Ostomy Continence Nurs. 1998; 25: 256-260.
86. Kahan H., Schwartzman J., Sawicky HH A new topical remedy for the prevention and management of napkin dermatitis (diaper rash). Arch Pediatr. 1956; 73: 12-29.
87. Kaessler HW Dermatitis of the diaper area: a new remedy for an old affliction. Arch Pediatr. 1957; 74: 47-50.
88. Bleiberg J., Saltzman JA Experience with a new preparation in the local treatment of psoriasis. Clin Med. 1958; 5: 485-488.
89. Clyman SG Clinical experience with a new preparation for psoriasis: a paired comparative study. Ann NY Acad Sci. 1958; 73: 1032-1037.
90. Welsh AL, Ede M. Therapeutic effectiveness of tar-allantoin lotion (Alphosyl ®) in selected dermatoses. Ohio Med. 1959; 55: 805-807.
91. Meister B. Treatment with tar and allantoin cream. Skin. 1962; 1: 55-56.
92. Allenby CF, Munro-Ashman EJE, Wells RS, Barr A. Outpatient treatment of psoriasis a double-blind trial of ointments. Lancet. 1966; 15: 124-125.
93. Herdenstam CG Allantoin in the treatment of psoriasis: a double blind study. Acta Derm Venereol. 1959; 39: 216-214.
94. Almeyda J., Wood H. Treatment of psoriasis: comparative study using allantoin coal tar extract combined with hydrocortisone and betamethasone valerate. Br J Clin Prac. 1979; 33: 106-108.
95. Willital GH, Heine H. Efficacy of Contracubex® Gel in the treatment of fresh scars after thoracic surgery in children and adolescents. Int J Clin Pharm Res. 1994; 14: 193-202.
96. Garnick JJ, Singh B., Winkley G. Effectiveness of a medicament containing silicon dioxide, aloe, and allantoin on aphthous stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 86: 550-556.
97. Wadhams PS, Griffith J., Nikravesh P., Chodosh D. Efficacy of a surfactant, allantoin, and benzalkonium chloride solution for onychomycosis. J Am Podiatr Med Assoc. 1999; 89: 124-130.
98. Willats WGT, McCarney L., Mackie W., Knox JP Pectin: cell biology and prospects for functional analysis. Plant Mol Biol. 2001; 47: 9-27.
99. Bacic A. Breaking an impasse in pectin biosynthesis. Proc Natl Acad Sci U S A. 2006; 103: 5639-5640.